Sara Hurvitz, MDDirector, Breast Cancer Clinical Research Program
Part 1/2 on a discussion of Managing Breast Cancer. Part 2 will be presented on Wednesday, October 27. To access both presentations 2 weeks post-ClinicalXchange, please click HERE to reach the CCS website Resource Center.
*Describe the mechanistic rationale for using phosphoinositide 3-kinase (PI3K) inhibitors as treatment for breast cancer.
*Summarize best practice recommendations for selecting patients who may benefit from treatment with PI3K inhibitors.
*Review key clinical trial data surrounding the use of novel and emerging PI3K inhibitors for the treatment of breast cancer.
Advanced, metastatic breast cancer is incurable. However, treatment may be effective in reducing tumor burden, alleviating symptoms, prolonging progression, and providing palliation. The development of PI3K inhibitors has expanded the arsenal of therapeutic options for patients with breast cancer. This short and succinct teaching module teaches clinicians the ins and outs of using PI3K inhibitors as treatment for breast cancer, including its mechanistic role in addressing the underlying pathophysiology of this type of cancer, evidence-based recommendations for selecting candidates for PI3K inhibitor therapy, and key clinical data on available and emerging PI3K agents.
This event is sponsored by Clinical Care Solutions and is not sponsored by industry.